These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautione ...

SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced that it has entered into an Interest Deferral Agreement (the “Agreement”) with Hanmi Pharmaceutical Co., Ltd. (“Hanmi”), whereby Hanmi has agreed to further defer the interest payment due un ...

Key Takeaways GH raised 2025 revenue guidance to $880-$890M, driven by rising test volume and ASPs. TEM posted 75% revenue growth and a $200M foundation model deal but remains unprofitable. GH expects breakeven for non-screening ops by Q4 2025, with lower cash burn excluding Shield.Tempus AI (TEM) and Guardant Health (GH) are two dominant players in the field of AI-powered precision oncology. Tempus, newly public and rapidly scaling, reported a 75% year-over-year revenue growth in the first quarter of 202 ...

Carrying a Zacks Rank #3 (Hold) at present, the laboratory service provider is concentrating more on areas that represent major growth opportunities and are expected to grow significantly faster than other therapeutic areas. It maintains a solid pipeline of potential acquisitions that fit its financial strategy and will enhance its organic growth. Additionally, the success of the LaunchPad initiative and a solid financial footing are highly encouraging for the company. Based in Burlington, NC, Labcorp offer ...

The cancer diagnostic firm Caris Life Sciences is set to list on the NASDAQ today. The company actually priced its IPO at $21 a share. That was above its expected range.Joining us right now is David Dean Halbert. He is Caris Life Scienc's founder, chairman, and CEO. And David, welcome.Thank you, Becky. Uh let's talk a little bit about what your company does because it's really interesting AI using life sciences to try and go after identify tumors and and find unique ways to deal with each of those cancer tu ...

I-Mab (IMAB) Conference June 17, 2025 10:00 AM ET Speaker0 Great. We'll get started now. I'd like to welcome everybody to HCW's at home series. Today, we're hosting EyeMed Biopharma. My name is Andres Malvinato. I'm a senior health care analyst here at HC Wainwright, and it's my pleasure to host, you today. And it's my pleasure to introduce, IMAD Biopharma's chief executive officer, Sean Fu, and IMAD's chief medical officer, Philip Dennis. So the crux of our fireside chat will be to give you an overview of ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 sha ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the u ...

Prelude Therapeutics (PRLD) 2025 Conference June 05, 2025 03:10 PM ET Speaker0 Alright. Welcome, everyone, to Jeffrey twenty twenty five Healthcare Global Conference. And then my name is Roger Song, one of the senior analysts cover SMICAP biotech in The US. It's my pleasure to have the next fireside chat with Peru Therapeutics. We have the whole team here. We have the CEO, Chris, and then President, then CMO, Jim, and then the CSO, Peggy. Welcome, everyone. Thanks. Awesome. Great. Yeah. Speaker1 Thanks, Rog ...

Summary of Exact Sciences (EXAS) FY Conference Call - June 03, 2025 Company Overview - Exact Sciences is focused on cancer detection and prevention, particularly through its flagship product, Cologuard, which screens for colon cancer using stool samples [3][4][5] - The company aims to eradicate cancer by preventing it, detecting it earlier, and guiding treatment [5] Key Points and Arguments Business Model and Growth - Exact Sciences has invested over $1 billion into its technology platform, which is designed to serve consumers, patients, health systems, and payers [5] - The company expects to generate over $3 billion in revenue this year, with a focus on growing profitability [7] - Cologuard has significantly increased colon cancer screening rates from approximately 60% to over 72% in the population over 50 years old [9] - The company has screened 20 million people with Cologuard, which is protected for three years, contributing to double-digit revenue growth [9][10] Technology and Innovation - Exact Sciences has developed a technology platform called Exact Nexus, built on the Epic EMR system, which enhances billing efficiency and electronic ordering [15][16] - The company is launching three new products this year, including Cologuard Plus, OncoDetect, and CancerGuard, which aim to improve cancer detection rates [36][37][38] - Cologuard Plus has a sensitivity of 95% and a specificity of 94%, detecting 43% of precancerous polyps [25][26] Market Opportunity - There are 55 million people in the U.S. who are not up to date with colon cancer screening, representing a significant growth opportunity for Exact Sciences [24] - The company anticipates increasing the number of people tested annually from 4 million to at least 14 million [24] - The market for care gap programs, driven by payers and health systems, is expected to grow into a billion-dollar opportunity [31] Financial Performance - Exact Sciences has achieved a 16% growth rate over the past five years, with a projected 14% growth in its screening portfolio this year [46] - The company turned adjusted EBITDA positive two years ago and expects to double profitability within two years [47] - Gross margins are nearly 75%, with significant margin expansion expected from the launch of Cologuard Plus and general administrative optimization [48][49] Future Outlook - The company is positioned for sustainable growth through its innovative products and technology platform, with a long-term revenue objective of mid-teens growth and over 20% adjusted EBITDA [50] - Exact Sciences emphasizes the importance of early detection and intervention in reducing cancer mortality rates [51] Additional Important Information - The company has a strong focus on clinical evidence, with multiple publications in reputable journals supporting its products [13] - Exact Sciences is working with nine of the top ten payers to enhance screening rates, which is crucial for qualifying for Medicare Advantage and commercial bonuses [20] - The company is leveraging AI and machine learning to improve performance and guide treatment decisions [35]